Effective targeting of the epidermal growth factor receptor (EGFR) for treating oral cancer: a promising approach

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Oral cancer, particularly oral squamous cell carcinoma, presents a significant global health challenge with high incidence and poor survival rates.
• The Epidermal Growth Factor Receptor (EGFR) family, a group of receptor tyrosine kinases, plays a crucial role in cellular functions.
• EGFR (ErbB-1/HER1) is implicated in the pathogenesis of oral carcinoma, with its overexpression linked to adverse outcomes.

Purpose of the Study:

• To review the role of the EGFR pathway in oral cancer.
• To focus on EGFR's involvement in the carcinogenesis process.
• To discuss therapeutic approaches targeting EGFR in oral cancer.

Main Methods:

• Literature review of studies on EGFR in oral carcinoma.
• Analysis of EGFR's function in biological processes like proliferation and migration.
• Examination of the correlation between EGFR variations, mutations, and tumor formation.

Main Results:

• EGFR overexpression is associated with poor prognosis in oral cancer.
• EGFR activation contributes to the malignant phenotype, inhibits apoptosis, and increases metastatic potential.
• EGFR variations and mutations may influence the effectiveness of EGFR inhibitors.

Conclusions:

• The EGFR pathway is a critical factor in oral cancer development and progression.
• Understanding EGFR's role is essential for developing targeted therapies.
• EGFR inhibitors represent a potential therapeutic avenue for oral cancer treatment.